The investigators were unable to report any ergogenic benefit in

The investigators were unable to report any ergogenic benefit in regards to time to exhaustion in the sprint test. In addition, the investigators also reported a greater loss in plasma volume in subjects consuming fluids with betaine than subjects consuming fluids that did not contain betaine. They suggested that perhaps a longer supplementation period AG-120 in vitro would be necessary to realize any ergogenic benefit, and that possibly the use of other

modes of exercise may provide a different outcome. Subsequently, Maresh and colleagues [13] examined 14-days of betaine supplementation on strength and power performance in recreationally trained men. They found no significant changes in repetitions Pexidartinib datasheet performed in the squat or bench press exercise, but they did find significant improvements in bench press throw power, isometric bench press force, vertical jump power and isometric squat force. Considering that this was the only study to have shown significant performance benefits from betaine supplementation in humans, additional research is warranted to confirm these results and to provide further insight to betaine supplementation. Thus, the purpose

of this study was to examine the efficacy of 15 days of betaine supplementation on muscle endurance, power performance and rate of fatigue in active college-aged men. Methods Subjects Twenty-four male subjects volunteered for this study. Following an explanation of all procedures, risks, and benefits, each subject gave his informed consent to participate in this study. The Institutional Review Board of the College of New Jersey approved the research protocol. Subjects were not permitted to use any additional nutritional supplementation and did not consume anabolic steroids or any other anabolic agents known to increase performance. Screening for steroid use and additional supplementation was accomplished via a health questionnaire filled out during subject recruitment. All subjects were recreationally active for at least the past three months including participation in a resistance training program. Subjects were matched for size and strength and were randomly assigned

to one of two groups. The first group (BET; 20.4 ± 1.3 years; height: 176.8 ± 6.6 cm; body mass: 77.8 ± 13.4 kg; body fat %: 11.6 ± 4.0%) consumed the supplement daily, and the second group (PL; 21.4 ± 4.7 years; height: 181.3 ± 5.9 cm; body mass: 83.3 ± 5.2 kg; body fat %: 12.0 ± 3.0%) consumed a placebo. The study was conducted in a double-blind Tozasertib mouse format. Study Protocol Subjects reported to the Human Performance Laboratory (HPL) on seven separate occasions. On the first visit subjects were tested for maximal strength [one repetition-maximum (1-RM)] on the squat and bench press exercises. The subsequent six visits occurred within three testing periods (T1 – T3), each separated by 7 days. Each testing period involved two days of assessment.

Comments are closed.